GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Anebulo Pharmaceuticals ANEB · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.29

+5.45%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Anebulo Pharmaceuticals

From its filings with the US Securities and Exchange Commission

SEC filings

Anebulo Pharmaceuticals is based in Lakeway, Texas and is incorporated in Delaware. Its shares trade on OTC under the ticker ANEB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 June 2025, it reported a net loss of $8.5m. At that date it held total assets of $12.1m and shareholders' equity of $11.7m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
7 May 2021
Employees
2
Website
anebulo.com ↗
Head office
C/O ANEBULO PHARMACEUTICALS, INC., LAKEWAY, TX, 78734
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Anebulo Pharmaceuticals Inc. is headquartered in Lakeway, Texas, providing a specific operational base in the US.
  • The company employs 2 full-time employees, indicating a lean organizational structure.
  • ANEB-001 is a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1) developed for acute cannabinoid intoxication.

Weaknesses

  • The company has only 2 employees, which limits operational capacity and resources.
  • Anebulo Pharmaceuticals Inc. is listed in the US, restricting its primary market presence to one country.
  • The firm is in the exploration stage of developing novel solutions, lacking approved commercial products.

Opportunities

  • The company can address the unmet medical need for a therapy to treat acute cannabinoid intoxication (ACI).
  • ANEB-001 is an orally bioavailable treatment that may rapidly reverse symptoms of ACI and reduce recovery time.
  • The firm is engaged in developing solutions for substance addiction, expanding beyond acute intoxication treatment.

Threats

  • CB1 receptors are concentrated in the brain and central nervous system, posing specific biological challenges for ANEB-001.
  • The signs and symptoms of ACI range from profound sedation to psychosis with hallucinations, complicating treatment outcomes.
  • CB2 receptors are found in peripheral organs and associated with the immune system, potentially introducing off-target effects.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.